492 results on '"Karapetis, Christos S."'
Search Results
2. Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy
3. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
4. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials
5. Immunotherapy use in oesophagogastric cancers—a review of the literature
6. Data from Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
7. Supplementary Data 1 from Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
8. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol
9. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
10. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
11. Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites
12. The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17.
13. Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
14. Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
15. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
16. Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome
17. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
18. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
19. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
20. Serum vitamin D decreases during chemotherapy: An Australian prospective cohort study
21. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.
22. Checkpoint inhibitor therapy for breast cancer, colon cancer, merkel cell carcinoma and sarcoma
23. Online information and support needs of women with advanced breast cancer: a qualitative analysis
24. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
25. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing
26. Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis
27. Supplementary Data: R analysis code from Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
28. Primer Sequences from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
29. Supplementary Data from Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
30. Supplementary Results from Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
31. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
32. Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer
33. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
34. Assessment of Successful Randomization Through a Machine Learning and Visualization Tool for Pre-Treatment Symptoms: Examples from CCTG/AGITG CO.17 and CO.20 Trials
35. Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
36. A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes.
37. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
38. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus
39. 280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY
40. DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary
41. Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials
42. Response to: “Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases”
43. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
44. Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors
45. Additional file 1 of A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol
46. Additional file 2 of A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol
47. Additional file 3 of A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol
48. Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer
49. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
50. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.